Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.amsu.2020.06.018 http://scihub22266oqcxt.onion/10.1016/j.amsu.2020.06.018 32637086!7327024!32637086     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Med+Surg+(Lond) 2020 ; 56 (ä): 125-127 Nephropedia Template TP {{tp|p=32637086|t=2020. A severe refractory COVID-19 patient responding to convalescent plasma; A case series |pdf=|usr=}}{{32637086}} gab.com Text A severe refractory COVID-19 patient responding to convalescent plasma; A case series JO: Ann Med Surg (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=32637086 #FOAvip INTRODUCTION: Although some medicines are under research, currently, no specific antiviral drug has been approved to target 2019 novel coronavirus. In this report two severe cases of 2019 novel coronavirus disease (COVID-19) patients have been described who received convalescent plasma (CP). CASE REPORT: Two male cases (a 46-year-old and a 56-year-old) after being diagnosed with severe COVID-19, they deteriorated despite supportive care and antiviral therapy. They started to improve with CP infusion both clinically and radiologically. Finally they were discharged in a very well condition with negative virology tests. CONCLUSION: CP might be an effective therapy for severe COVID-19 patients. Twit Text FOAVip A severe refractory COVID-19 patient responding to convalescent plasma; A case series ????Ann Med Surg (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=32637086 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32637086 #FOAvip English Wikipedia <ref>{{Cite pmid|32637086}}</ref> A severe refractory COVID-19 patient responding to convalescent plasma; A case series #MMPMID32637086 Abdullah HM; Hama-Ali HH; Ahmed SN; Ali KM; Karadakhy KA; Mahmood SO; Mahmood ZH; Hamad Amin KQ; Atta PM; Nuradeen BE; Mohammed SH; Salih RQ; Baba HO; Kakamad FH Ann Med Surg (Lond) 2020[Aug]; 56 (ä): 125-127 PMID32637086show ga INTRODUCTION: Although some medicines are under research, currently, no specific antiviral drug has been approved to target 2019 novel coronavirus. In this report two severe cases of 2019 novel coronavirus disease (COVID-19) patients have been described who received convalescent plasma (CP). CASE REPORT: Two male cases (a 46-year-old and a 56-year-old) after being diagnosed with severe COVID-19, they deteriorated despite supportive care and antiviral therapy. They started to improve with CP infusion both clinically and radiologically. Finally they were discharged in a very well condition with negative virology tests. CONCLUSION: CP might be an effective therapy for severe COVID-19 patients. äA severe refractory COVID-19 patient responding to convalescent plasma(epmc).pdf DeepDyve Pubget Overpricing